Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00060710 · ClinicalTrials.gov registry record · Phase 2
CP-461 in the Treatment of Patients With Advanced Melanoma
A Phase 2 study, sponsored by Astellas Pharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT00060710 is a Phase 2 study that was terminated before completion, run by Astellas Pharma. The registered enrollment target is 35 participants.
The verdict
NCT00060710, a Phase 2 study, was terminated before completion, sponsored by Astellas Pharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy of CP-461 given twice daily orally in patients with advanced or metastatic malignant melanoma and to evaluate the safety profile of CP-461 in this patient population.
Interventions
- DRUG CP-461
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2003-01 |
| Est. Completion | 2004-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00060710
The ClinicalTrials.gov registry entry for NCT00060710 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CP-461 is the first listed.
NCT00060710 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00060710 about?
NCT00060710 is a clinical study titled "CP-461 in the Treatment of Patients With Advanced Melanoma". The purpose of this study is to determine the efficacy of CP-461 given twice daily orally in patients with advanced or metastatic malignant melanoma and to evaluate the safety profile of CP-461 in this patient population.
What is the current status of trial NCT00060710?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2003-01. Estimated completion is 2004-12.
What interventions are being tested in trial NCT00060710?
The interventions under investigation include: CP-461 (DRUG).
Who is sponsoring clinical trial NCT00060710?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.